<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00496457</url>
  </required_header>
  <id_info>
    <org_study_id>WN29860</org_study_id>
    <secondary_id>EudraCT Number: 2006-004545-42</secondary_id>
    <secondary_id>TRO19622 CLEQ 1104-1</secondary_id>
    <nct_id>NCT00496457</nct_id>
  </id_info>
  <brief_title>Efficacy Study With 500 mg QD of TRO19622 vs Placebo in Patients With Painful Peripheral Diabetic Neuropathy</brief_title>
  <official_title>A Double-Blind, Randomized, Multicenter Study With 500 mg QD of TRO19622 Versus Placebo in Patients With Painful Peripheral Diabetic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ergomed GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of TRO19622 administered PO
      daily for 6 weeks compared to placebo administered PO daily in patients with painful
      peripheral diabetic neuropathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic peripheral neuropathic pain (DPNP) affects approximately 11% of patients with
      diabetic peripheral neuropathy (DPN). Diabetic neuropathy as the underlying disease is the
      most common long-term complication of diabetes mellitus estimated to be experienced by a
      majority of patients at least in a mild manner.

      Many patients with (DPNP) do not respond adequately to any individual treatment option. None
      of the various treatments used can be considered a cure. As a result, although a variety of
      drugs are available for the treatment of diabetic neuropathic pain, there is a strong need to
      develop new drugs with greater efficacy and/or fewer adverse effects.

      The primary objective of the study is to compare the effect of TRO19622 versus placebo on the
      24h neuropathic pain scores during the last 7 days of the 6-week treatment period.

      Secondary objectives are to compare the efficacy on neuropathic pain, impact on emotional
      functioning, safety profile, pain time course, and response rate of TRO19622 versus placebo.
      Additionally, the pharmacokinetics of TRO19622 will be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of TRO19622 versus Placebo on the mean 24h neuropathic pain score on the Likert numerical rating scale.</measure>
    <time_frame>During the last 7 days of the 6-week treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>24h Pain time course</measure>
    <time_frame>Duration of study (within 11weeks after screening)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis for treatment effects: SF-MPQ, SF-BPI, SF36, POMS, Global Impression of Change (Patient / Investigator)</measure>
    <time_frame>Within 6 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>During the course of the study.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Diabetic Neuropathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TRO19622</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental</intervention_name>
    <description>Capsules of TRO19622 (125 mg)- Once a day before noon meal during 6 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo comparator</intervention_name>
    <description>4 Capsules of PBO per day before noon meal</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be a male &gt;18 years or a post-menopausal female (&gt;60 years of age and at least 1 year
             of amenorrhea).

          -  Have painful diabetic neuropathy of &gt;6 months duration and are either pain treatment
             naive or have important side effects or inadequate relief from their current pain
             medication.

          -  Be on current pain medication (prescribed analgesics), stable for at least 3 months
             before study entry (± 25% dosage of basic pain medication, top-up rescue medication
             allowed), or pain treatment naive.

          -  Have stable diabetes, defined as HbA1c &lt;10%, no changes in medication in the previous
             3 months, and no new symptoms associated with diabetes in the previous 3 months.

          -  Have scored &gt;2 points on the Michigan Neuropathy Screening Instrument (MNSI), part
             B-physical assessment by health professional.

          -  Have an ECG without any clinically significant abnormality.

        The following inclusion criteria should be ascertained at the baseline visit:

          -  Have measurable pain perception (previous 24h) on the Likert numerical rating scale
             with a mean≥4.0 points calculated from at least 4 daily measurements over the 7 days
             immediately prior to the Baseline Visit.

          -  Have stopped current pain medication at least 14 days prior to the Baseline Visit
             (except rescue medication).

        Exclusion Criteria:

          -  Be pregnant female, lactating female, or female of child bearing potential (≤60 years
             of age).

          -  Have a documented neuropathy of any cause other than those mentioned in the inclusion
             criteria which might interfere with the assessment of the severity of pain (eg,
             including, but not limited to, alcoholic, uremic, B12, TSH, chemotherapy, HIV, post
             surgical, or post-traumatic neuropathy).

          -  Have other neurological diseases that may produce weakness, sensory loss, or autonomic
             symptoms, or laboratory test abnormality.

          -  Have been on pain treatment with strong opioids, more than 4 different drug regimens
             in the previous year, or a current combination of more than 2 drugs.

          -  Have a current medication of lipid lowering agents other than statins.

          -  Have a body mass index (BMI) &gt;40 kg/m2 (obesity grade III).

          -  Had any surgery within the previous 2 months.

          -  Have concurrent serious neurological disease (eg, dementia, multiple sclerosis, or any
             other disease that would impact the ability of the patient to provide consent for
             study participation).

          -  Have a recent history (within the previous 6 months) or current evidence of alcohol or
             drug abuse.

          -  Have concurrent unstable disease involving any system (eg, advanced carcinoma,
             myocardial infarction, clinical or ECG signs of myocardial ischemia, cardiac
             insufficiency i.e.≥ NYHA functional classification class 2, anginal symptoms, current
             symptoms of CAD, renal impairment, or any other condition that in the opinion of the
             Investigator would make the patient unsuitable for study participation).

          -  Participated in any other investigational drug or therapy study within the previous 3
             months.

          -  Changed or interrupted current well-tolerated medication during the previous 3 months.

          -  Lack of ability or willingness to give informed consent.

          -  Be possibly dependent on the Investigator or the Sponsor (eg, including, but not
             limited to, affiliated employee).

          -  Have hemostasis disorders or a current treatment of anticoagulants.

          -  Have non-adequate renal and/or hepatic function as follows:

               -  Renal - Blood creatinine &gt;1.5X upper limit of normal (ULN)

               -  Hepatic - Liver enzymes (ALT and AST) &gt;2 X ULN

          -  Have a known history of or current cardiac dysrhythmias and / or a known history of or
             current cardiovascular disease including myocardial infarction except patients with
             well controlled hypertension only.

          -  Are not able to comply with regard to the known contraindications, warnings and
             precautions, drug-interactions and dosing recommendations of paracetamol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Louis Abitbol, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Trophos, Parc Scientifique de Luminy - Case 931, Luminy Biotech Enterprises, 13288 Marseille Cedex9 - France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dan Ziegler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>German Diabetes Center, German Diabetes Clinic, Leibniz Institute at the Heinrich-Heine University, Auf ´m Hennekamp 65, 40225 Dusseldorf, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univerity Hospital OSIJEK, Department for Diabetes and Endocrinology, J.Huttlera 4</name>
      <address>
        <city>Osijek</city>
        <zip>31 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genaral Hospital &quot;Josip Bencevic&quot;, Internal Medicine Department-Unit for Diabetes, Andrije Stampara 42</name>
      <address>
        <city>Slavonski Brod</city>
        <zip>35 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Varazdin, Internal Medicine Department-Unit for Diabetes, Ivana Mestrovica bb</name>
      <address>
        <city>Varazdin</city>
        <zip>42 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital &quot;Dubrava&quot;, University Department for Internal Medicine, Institut for Diabetes, Endocrinology and Metabolic diseases, Avenija Gojka Suska 6</name>
      <address>
        <city>Zagreb</city>
        <zip>10 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Zentrum Mergentheim - Theodor-Klotzbücher-Straße 12</name>
      <address>
        <city>Bad Mergentheim</city>
        <zip>97980</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetologische Schwerpunktpraxis - Wilhelminenstr. 22</name>
      <address>
        <city>Dinslaken-Bruch</city>
        <zip>46537</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Diabetes Center, Institut für Klinische Diabetologie, Leibniz-Zentrum an der Heinrich-Heine Universität - Auf'm Hennekamp 65</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Region Hannover GmbH - Klinikum Hannover Nordstadt - Diabetes Schwerpunktklinik -Medizinische Klinik - Haltenhoffstr. 41</name>
      <address>
        <city>Hannover</city>
        <zip>30167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg - Abteilung Innere Medizin I und klinische Chemie - Im Neuenheimer Feld 410</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pro scientia med - Osterweide 10</name>
      <address>
        <city>Lübeck</city>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IKFE GmbH - Institut für klinische Forschung und Entwicklung - Parcusstr. 8</name>
      <address>
        <city>Mainz</city>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Schwerpunktpraxis - Gesundheitszentrum Potsdam GmbH - Hebbelstr. 1A</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Schwerpunktpraxis - Gesundheitszentrum Potsdam GmbH, Hebbelstr. 1A</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sophien- und Hufeland-Klinikum gGmbH - Klinik für Neurologie und Klinische Neurophysiologie - Henry-van-de-Velde-Str. 2</name>
      <address>
        <city>Weimar</city>
        <zip>99425</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daugavpils Regional Hospital - Vasarnicu street 20</name>
      <address>
        <city>Daugavpils</city>
        <zip>LV-5420</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zemgale's Diabetes Centre SIA - Zemgales boulevard 15</name>
      <address>
        <city>Jelgava</city>
        <zip>LV-3000</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctor's Practice in Endocrinology - Meža prospekts 9, 2nd floor, 41.kabinets</name>
      <address>
        <city>Ogre</city>
        <zip>LV-5001</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Centre &quot;Riga&quot; - Katrinas dambis 16</name>
      <address>
        <city>Riga</city>
        <zip>LV-1045</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Talsu Hospital - Rugena street 7</name>
      <address>
        <city>Talsi</city>
        <zip>LV-3201</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Specjalistyczny Ośrodek, Internistyczno-Diabetologiczny, ul Zamenhofa 10/20</name>
      <address>
        <city>Białystok</city>
        <zip>15-435</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Neurologii Klinicznej - Ul. Dwernickiego 8</name>
      <address>
        <city>Kraków</city>
        <zip>31-530</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Special-Med. Ul. Weteranów 46</name>
      <address>
        <city>Lublin</city>
        <zip>20-044</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ MEDICA, ul. Jutrzenki 4</name>
      <address>
        <city>Lublin</city>
        <zip>20-538</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Beta-Med., Plac Wolności 17</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-073</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adamiec Rajmund Gabinet Lekarski, ul. Żelazna 34</name>
      <address>
        <city>Wrocław</city>
        <zip>53-428</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre of Neurology, Clinical Hospital Centre &quot;Dr Dragisa Misovic&quot;</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic for Neurology and Psychiatry, Clinical Hospital Centre &quot;Zvezdara&quot;</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Endocrinology, Clinical Centre Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Clinic, Military Medical Academy</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Department, Clinical Hospital Zemun</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Neurology, Clinical Centre &quot;Kragujevac&quot;</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
    <country>Germany</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Serbia</country>
  </location_countries>
  <removed_countries>
    <country>Former Serbia and Montenegro</country>
  </removed_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2007</study_first_submitted>
  <study_first_submitted_qc>July 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2007</study_first_posted>
  <last_update_submitted>November 21, 2016</last_update_submitted>
  <last_update_submitted_qc>November 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Neuropathy</keyword>
  <keyword>Painful Peripheral Diabetic Neuropathy</keyword>
  <keyword>TRO19622</keyword>
  <keyword>Trophos</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

